12th Annual FDA/Alzheimer’s Disease Allies Meeting

Diversifying the Therapeutic Pipeline for Alzheimer’s Disease: From Targets to Trials

The Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition’s 12th annual meeting will explore the current therapeutic landscape for AD from discovery and validation of novel targets through clinical testing of novel drug candidates and non-pharmacologic interventions.

The meeting will also provide a forum for receiving updates on the National Institutes of Health’s investments in a precision medicine approach to the development of Alzheimer’s disease treatment and prevention. A series of expert presentations will be followed by a robust discussion with the leadership of the National Institute on Aging, CMS, and the FDA’s Division of Neurology Products. These discussions will help to assist the field in more rapidly deploying knowledge to develop and deliver effective pharmacologic and non-pharmacologic therapeutic approaches for AD.

Registration Inquiry
File Attachments


Samantha Budd Haeberlein


Jinhe Li, Ph.D.

US Green Valley Pharmaceuticals

Suzana Petanceska, Ph.D.

National Institute on Aging

Ben Readhead, MBBS

Arizona State University

Catherine Kaczorowski, Ph.D.

Jackson Labs

Gabriela Chiosis, Ph.D.

Memorial Sloan Kettering Cancer Center

Laurie Ryan, Ph.D.

National Institute on Aging

Laura Baker, Ph.D.

Wake Forest Medical School

Frank Longo, M.D., Ph.D.


Mark Gurney, Ph.D., MBA

Tetra Therapeutics